Stockscreener 앱 받기
7.23
1.23%
-0.09
시간 외 거래:
7.23
전일 마감가:
$7.32
열려 있는:
$7.35
하루 거래량:
872.50K
Relative Volume:
1.05
시가총액:
$514.56M
수익:
$133.62M
순이익/손실:
$-177.37M
주가수익비율:
-2.5017
EPS:
-2.89
순현금흐름:
$23.50M
1주 성능:
-9.40%
1개월 성능:
-12.58%
6개월 성능:
-57.57%
1년 성능:
-54.98%
1일 변동 폭
$7.09
$7.6034
1주일 범위
$7.07
$8.21
52주 변동 폭
$7.07
$27.24
Xencor Inc Stock (XNCR) Company Profile
명칭
Xencor Inc
전화
626-305-5900
주소
465 N. HALSTEAD ST., PASADENA, CA
XNCR을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
XNCR
Xencor Inc
|
7.23 | 533.07M | 133.62M | -177.37M | 23.50M | -2.89 |
|
VRTX
Vertex Pharmaceuticals Inc
|
366.54 | 98.88B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.00 | 58.84B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
438.93 | 56.12B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
661.83 | 41.20B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.18 | 35.49B | 3.81B | -644.79M | -669.77M | -6.24 |
Xencor Inc Stock (XNCR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-04-21 | 개시 | William Blair | Outperform |
| 2024-12-12 | 개시 | Wells Fargo | Overweight |
| 2024-12-02 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2024-04-16 | 재확인 | BTIG Research | Buy |
| 2024-02-28 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2023-05-19 | 개시 | BofA Securities | Buy |
| 2022-12-06 | 개시 | Cowen | Outperform |
| 2022-10-13 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2022-09-21 | 개시 | JP Morgan | Overweight |
| 2022-07-06 | 재개 | Canaccord Genuity | Buy |
| 2022-02-11 | 개시 | BMO Capital Markets | Outperform |
| 2022-01-21 | 개시 | SMBC Nikko | Outperform |
| 2021-12-15 | 개시 | H.C. Wainwright | Buy |
| 2021-10-15 | 재개 | BTIG Research | Buy |
| 2021-02-24 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2020-03-04 | 개시 | Barclays | Underweight |
| 2020-02-25 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2020-01-30 | 개시 | RBC Capital Mkts | Outperform |
| 2019-11-20 | 재개 | Guggenheim | Neutral |
| 2019-08-07 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2019-08-07 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2019-06-13 | 개시 | Mizuho | Buy |
| 2019-04-12 | 개시 | Guggenheim | Buy |
| 2019-03-27 | 개시 | Berenberg | Buy |
| 2019-03-15 | 개시 | Raymond James | Outperform |
| 2018-09-10 | 재개 | BTIG Research | Buy |
| 2018-03-28 | 재개 | Leerink Partners | Outperform |
| 2017-03-02 | 개시 | Instinet | Neutral |
| 2017-03-02 | 재확인 | Wedbush | Outperform |
| 2016-10-04 | 개시 | Piper Jaffray | Overweight |
| 2015-12-22 | 개시 | Canaccord Genuity | Buy |
| 2015-08-05 | 재확인 | MLV & Co | Buy |
| 2015-02-12 | 재확인 | Oppenheimer | Outperform |
| 2015-01-28 | 재확인 | MLV & Co | Buy |
| 2014-07-11 | 개시 | Oppenheimer | Outperform |
모두보기
Xencor Inc 주식(XNCR)의 최신 뉴스
Xencor, Inc. (NASDAQ:XNCR) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates - uk.finance.yahoo.com
Xencor price target lowered to $26 from $31 at Wedbush - Yahoo Finance
Xencor’s XmAb541 Study Completion: A Potential Game-Changer in Oncology - TipRanks
Xencor’s XmAb808 Study: A New Frontier in Cancer Treatment - TipRanks
Xencor’s XmAb541 Study: A Promising Step in Cancer Treatment - TipRanks
Xencor’s XmAb942 Shows Promising Efficacy and Strategic Advancements, Earning a Buy Rating - TipRanks
Wedbush Cuts Price Target on Xencor to $26 From $31, Keeps Outperform Rating - MarketScreener
Xencor’s Strategic Advances and Promising Pipeline Drive Buy Rating - TipRanks
Xencor 2025 Q2 Earnings Strong Revenue Growth, 55.2% Reduction in Net Loss - AInvest
Xencor Reports Second Quarter 2025 Financial Results - BioSpace
Xencor, Inc. Reports Revenue Growth Amidst Continued Losses - TipRanks
Xencor Inc earnings beat by $0.31, revenue topped estimates - Investing.com Australia
Xencor: Q2 Earnings Snapshot - San Antonio Express-News
Xencor Q2 Earnings: Losses Reported but Revenue Surpasses ExpectationsNews and Statistics - IndexBox
Xencor (XNCR) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Finance
Xencor (XNCR) Q2 Revenue Jumps 82% - sharewise.com
Xencor, Inc.'s (NASDAQ:XNCR) Price Is Right But Growth Is Lacking - simplywall.st
Xencor Inc. Flashes Rebound Signal in Oversold ConditionConfirmed Setup With Expert Accuracy Supported - metal.it
How does Xencor Inc. generate profit in a changing economyRapid market gains - Jammu Links News
What is the dividend policy of Xencor Inc. stockMaximize portfolio value with expert tips - Jammu Links News
When is Xencor Inc. stock expected to show significant growthSuperior capital gains - Jammu Links News
What is Xencor Inc. company’s growth strategyLightning-fast growth - Jammu Links News
Is it the right time to buy Xencor Inc. stockSky-high return potential - Jammu Links News
How many analysts rate Xencor Inc. as a “Buy”Overwhelming profit margins - Jammu Links News
What catalysts could drive Xencor Inc. stock higher in 2025Strong return on investment - Jammu Links News
How does Xencor Inc. compare to its industry peersConsistent triple returns - Jammu Links News
Should I hold or sell Xencor Inc. stock in 2025Triple-digit growth rates - Jammu Links News
Is Xencor Inc. a growth stock or a value stockFree Expert Stock Watchlist - Jammu Links News
Is Xencor Inc. a good long term investmentCapitalize on market momentum for big wins - Jammu Links News
Xencor Appoints Raymond Deshaies to Board of Directors to Bolster Drug Development Efforts - AInvest
How volatile is Xencor Inc. stock compared to the marketJaw-dropping returns - Jammu Links News
Xencor XNCR 2025Q2 Earnings Preview Upside Potential on Robust Revenue Growth - AInvest
Pasadena-Based Biopharmaceutical Firm Xencor Names Veteran Scientist to Board - Pasadena Now
Xencor appoints biotech veteran Raymond Deshaies to board of directors By Investing.com - Investing.com India
Xencor Appoints Raymond Deshaies to Board of Directors - TipRanks
Xencor Appoints Raymond Deshaies, Ph.D., to Board of Directors - FinancialContent
Xencor’s XmAb819 Study: A Promising Step in Renal Cell Carcinoma Treatment - TipRanks
RSI Reset May Fuel Rebound in Xencor Inc.AI Based High Gain Watchlist Scanner Shared - metal.it
Why Xencor Inc. stock attracts strong analyst attentionTechnical Stock Breakout Predictions Signal Entry Points - metal.it
What is the risk reward ratio of investing in Xencor Inc. stockPowerful profit generation - jammulinksnews.com
Will Xencor Inc. Reverse From Oversold ConditionsROI Driven Equity Selection With Safety Emphasized - beatles.ru
Moving Average Trends for Xencor Inc. Stock: What They IndicateAnalyst Grade Signals - Newser
Price action breakdown for Xencor Inc.Free Early Breakout Entry Point Notifications - Newser
Signal strength of Xencor Inc. stock in tech scannersValue Investing Checklist with Entry Signals - Newser
Is Xencor Inc. stock overvalued or undervaluedGet exclusive market insights for better trading - Jammu Links News
Xencor, Inc. (NASDAQ:XNCR) Given Consensus Rating of “Moderate Buy” by Brokerages - Defense World
Xencor Inc (XNCR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.24%
3.39%
자본화:
|
볼륨(24시간):